Algernon (CSE:AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver to discuss another development for their repurposed drug Ifenprodil. Moreau giving Proactive more details about the study which will consist of 40 patients and will deal with those currently sick with the coronavirus.
Full interview: Algernon Announces Regulatory Submission for COVID trial in South Korea
Quick facts: Algernon Pharmaceuticals Inc.
Price: 0.35 CAD
Market Cap: $31.52 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE